BrainsWay Ltd. (BWAY)

Market Cap	459.68M +130.3%
Revenue (ttm)	49.09M +27.1%
Net Income	6.25M +316.5%
EPS	0.13 +213.1%
Shares Out	39.15M
PE Ratio	73.57
Forward PE	59.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,317
Open	23.19
Previous Close	23.41
Day's Range	22.91 - 23.77
52-Week Range	7.84 - 26.63
Beta	0.32
Analysts	Strong Buy
Price Target	26.50 (+14.52%)
Earnings Date	Mar 11, 2026

About BWAY

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 17, 2019
• Employees: 120
• Stock Exchange: NASDAQ
• Ticker Symbol: BWAY
• Website: https://www.brainsway.com

Analyst Summary

According to 2 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $26.5, which is an increase of 14.52% from the latest price.

Price Target

$26.5

(14.52% upside)

Analyst Consensus: Strong Buy